ArticleGastroenterology report2026
Predicting postoperative recurrence in colorectal cancer using MRI-derived radiomics features and their correlation with the tumor immune microenvironment.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The recurrence of colorectal cancer (CRC) after surgery poses a significant threat to patient recovery, but current prediction methods lack sensitivity. In this study, we aimed to develop a radiomics-based model for recurrence prediction and to investigate its association with the tumor immune microenvironment. Methods: A retrospectively cohort study was conducted with 197 patients from the Second Affiliated Hospital of Harbin Medical University (Harbin, China; training set) and 130 patients from Shandong First Medical University Affiliated Central Hospital (Jinan, China; validation set). Clinical characteristics and blood biomarkers (alpha-fetoprotein, carcinoembryonic antigen, and cancer antigen 19-9) were compared between the recurrence and nonrecurrence groups, and magnetic resonance imaging (MRI)-derived radiomics features were extracted by using 3D Slicer and PyRadiomics. After this, LASSO regression was used to identify key features, and univariate analysis was used to retain statistically significant predictors. A multivariate logistic regression model was then developed to predict recurrence, and the relationship between radiomics features and immune cells was subsequently explored by using a CRC mouse model. Results: There were no significant differences in the clinical characteristics between recurrence and nonrecurrence groups. The initial model, comprising 10 features, achieved an area under the curve (AUC) of 0.99 in the training set but only 0.6 in the validation set. After excluding six features, the refined model, which included original gray level co-occurrence matrix sum entropy (OGSE), log-sigma-3-0-mm-3D neighborhood gray tone difference matrix Busyness (LNB), original first order total energy (OFTE), wavelet-LLH gray level size zone matrix zone variance (WGZV), achieved an AUC of 0.98 in the validation set, outperforming traditional blood biomarkers. In a murine model, regulatory T cells exhibited a strong positive correlation with OGSE ( Conclusions: MRI-derived radiomics features, particularly OGSE, LNB, OFTE, and WGZV, can effectively predict postoperative CRC recurrence. These features are correlated with the tumor immune microenvironment, supporting the use of radiomics as a noninvasive tool for tumor assessment in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.